Gene therapy: a pharmacokinetic/pharmacodynamic modelling overview.
Since gene therapy started over 20 years ago, more than one-thousand clinical trials have been carried out. Nonviral vectors present interesting properties for their clinical application, but their efficiency in vivo is relatively low, and further improvements in these vectors are needed. Elucidating how nonviral vectors behave at the intracellular level is enlightening for vector improvement and optimization. Model-based approach is a powerful tool to understand and describe the different processes that gene transfer systems should overcome inside the body. Model-based approach allows for proposing and predicting the effect of parameter changes on the overall gene therapy response, as well as the known application of the pharmacokinetic/pharmacodynamic modelling in conventional therapies. The objective of this paper is to critically review the works in which the time-course of naked or formulated DNA have been quantitatively studied or modelled.
Parra-Guillén
Zinnia P
ZP
Department of Pharmacy and Pharmaceutical Technology School of Pharmacy, University of Navarra, Pamplona, Spain.
González-Aseguinolaza
Gloria
G
Berraondo
Pedro
P
Trocóniz
Iñaki F
IF
D015316:Genetic Therapy / Q000009:adverse effects / Q000639:trends; D005822:Genetic Vectors / Q000009:adverse effects / Q000493:pharmacokinetics; D006801:Humans; D008954:Models, Biological
Mol Ther. 2001 Nov;4(5):438-46
11708880
Gene Ther. 2003 Sep;10(20):1766-75
12939643
Gene Ther. 2005 Jul;12(13):1023-32
15815703
Mol Ther. 2004 Mar;9(3):443-51
15006612
Hum Gene Ther. 1995 May;6(5):553-64
7578393
Pharm Res. 2005 Jun;22(6):883-91
15948032
Hum Mol Genet. 1992 Sep;1(6):363-9
1301910
Cancer Res. 1997 Jul 1;57(13):2681-6
9205077
Gene Ther. 2008 Feb;15(4):247-56
18097470
Gene Ther. 2003 Mar;10(6):453-8
12621449
Drug Discov Today. 2003 Nov 1;8(21):990-6
14643162
Pharm Res. 2008 Dec;25(12):2720-2
18810328
Pharm Res. 2009 Jul;26(7):1581-9
19240986
Adv Drug Deliv Rev. 2005 Apr 5;57(5):769-80
15757760
J Pharm Sci. 1995 Nov;84(11):1267-71
8587040
Eur J Cancer. 2008 Jan;44(1):142-50
18039567
Biophys J. 2005 Sep;89(3):1574-88
15980163
Curr Mol Pharmacol. 2008 Jan;1(1):13-23
20021420
Pharm Res. 2002 Nov;19(11):1599-605
12458664
J Gene Med. 2007 Oct;9(10):833-42
17721874
Pharm Res. 2002 Apr;19(4):377-81
12033367
Clin Cancer Res. 2009 Apr 1;15(7):2352-60
19318482
J Control Release. 2007 Mar 12;118(1):118-25
17250923
J Pharm Sci. 1996 Jun;85(6):612-8
8773958
J Pharm Sci. 1998 Nov;87(11):1292-9
9811479
Gene Ther. 1997 Mar;4(3):226-37
9135736
Pharm Res. 2001 Jan;18(1):67-74
11336355
Int J Pharm. 2005 Aug 11;299(1-2):34-40
15964723
Hum Gene Ther. 1994 Jun;5(6):679-91
7948130
Biochem Biophys Res Commun. 1998 Oct 20;251(2):538-44
9792809
Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7297-301
7638184
Gene Ther. 1999 Jul;6(7):1258-66
10455434
Adv Genet. 2005;53:47-68
16240990
Adv Genet. 2005;54:3-20
16096005
Cancer Sci. 2008 May;99(5):856-62
18294288
Gene Ther. 2008 Aug;15(16):1131-8
18528432
Drug Discov Today. 2008 Apr;13(7-8):341-6
18405847
Eur J Pharm Sci. 2005 Nov;26(3-4):295-306
16102948
Pharm Res. 2007 Jun;24(6):1079-87
17387605
N Engl J Med. 1990 Aug 30;323(9):570-8
2381442
Mol Ther. 2006 Apr;13(4):786-94
16364692
Int J Pharm. 2008 Nov 3;363(1-2):192-8
18708133
Biotechnol Bioeng. 2010 Jan 1;105(1):195-209
19718701
Pharm Res. 1995 Jun;12(6):825-30
7667185
J Control Release. 2009 Jun 19;136(3):226-31
19249330
Adv Drug Deliv Rev. 2001 Nov 19;52(3):153-64
11718940
Hum Gene Ther. 2006 Mar;17(3):253-63
16544975
J Gene Med. 2007 May;9(5):369-80
17410613
Adv Drug Deliv Rev. 2005 Apr 5;57(5):675-88
15757754
Biol Pharm Bull. 2002 Mar;25(3):275-83
11913519
Eur J Pharmacol. 2008 Apr 28;584(2-3):318-27
18325493
Eur J Pharm Sci. 2009 Jun 28;37(3-4):418-26
19491033
J Gene Med. 2007 Jul;9(7):613-9
17534886
J Control Release. 2006 Feb 21;110(3):605-9
16360229
AAPS PharmSci. 1999;1(3):E9
11741205
Nat Biotechnol. 1998 Jan;16(1):80-5
9447599
Pharm Res. 2001 Sep;18(9):1277-83
11683240